Physician profile
Ryan Thomson Kellogg
NPI 1376805218
$245,179.64
in general payments reported to CMS, 2019-2025
20 companies · $61K in 2025
The $61K reported for 2025 was more than what 96% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,318 · 2020: $22K · 2021: $119K · 2022: $1,632 · 2023: $27K · 2024: $6,375 · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $27K · Food and Beverage: $4,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,574.13 |
| Travel and Lodging | $27,335.68 |
| Food and Beverage | $4,474.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viz.Ai, INC. | $107,910.94 | 2021-2022 | |
| Medical Device Business Services, INC. | $60,707.82 | 2023-2025 | Emboguard, Trufill, Cerepak Uniform |
| Siemens Medical Solutions USA, INC. | $37,377.43 | 2019-2025 | Artis Icono Floor, Artis Icono Biplane, Corpath Imaging System |
| Imperative Care, INC | $20,044.74 | 2020-2025 | Zoom 88-T Large Distal Platform, Zoom Reperfusion Catheter, Zoom Rdl Radial Access System, 103cm |
| Corindus INC. | $8,217.89 | 2019 | |
| Scientia Vascular | $7,617.98 | 2023-2024 | |
| Medtronic, INC. | $925.85 | 2022-2025 | Pipeline, Solitaire X, Onyx 18 |
| Depuy Synthes Sales INC. | $683.56 | 2021-2025 | Trufill, Embotrap |
| Nico Corporation | $500.00 | 2020 | |
| Penumbra, INC. | $262.40 | 2019-2025 | Penumbra Coil 400 |
| Stryker Corporation | $236.96 | 2021-2023 | Target |
| Integra Lifesciences Corporation | $138.89 | 2022 | |
| Inspiremd LTD | $121.00 | 2024 | Cguard |
| Depuy Synthes Products, INC. | $119.92 | 2023 | Galaxy G3 |
| Relievant Medsystems, INC. | $118.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $92.01 | 2022-2024 | Cosmos 18 Advanced, Hydrosoft Advanced, Web Aneurysm Embolization System |
| Balt USA, LLC | $45.76 | 2022-2023 | Hybrid Guidewire |
| Phenox INC. | $41.83 | 2022 | |
| Qapel Medical INC | $15.83 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,084.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.